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ABSTRACT 
Insulin resistance is an independent negative predictor of outcome after elective 
surgery and increases mortality among surgical patients in intensive care. The incretin 
hormone glucagon like peptide-1 (GLP-1) potentiates glucose-induced insulin release from 
the pancreas, but may also increase insulin sensitivity in skeletal muscle and directly suppress 
hepatic glucose release. Here, we investigated whether a perioperative infusion of GLP-1 
could counteract the development of insulin resistance after surgery. Pigs were randomly 
assigned to 3 groups; surgery/control, surgery/GLP-1 and sham/GLP-1. Both surgery groups 
were subjected to major abdominal surgery. Whole body glucose disposal (WGD) and 
endogenous glucose release (EGR) were assessed pre- and postoperatively using D-[6,6-2H2]-
glucose infusion in combination with hyperinsulinemic euglycemic step-clamping. In the 
surgery/control group, peripheral insulin sensitivity (i.e. WGD) was reduced by 44% relative 
to preoperative conditions, whereas the corresponding decline was only 9% for surgery/GLP-
1 (P < 0.05). Hepatic insulin sensitivity (i.e. EGR) remained unchanged in the surgery/control 
group, but was enhanced after GLP-1 infusion in both surgery and sham animals (40% and 
104%, respectively, both P<0.05). Intraoperative plasma glucose increased in surgery/control 
(~20%), but remained unchanged in both groups receiving GLP-1 (P < 0.05). GLP-1 
diminished an increase in postoperative glucagon levels, but did not affect skeletal muscle 
glycogen or insulin signalling proteins after surgery. We show that GLP-1 improves 
intraoperative glycemic control, diminishes peripheral insulin resistance after surgery and 
suppresses EGR. This study supports the use of GLP-1 to prevent development of 
postoperative insulin resistance. 
  
INTRODUCTION 
Insulin resistance arises after any trauma, including surgery. It is an independent 
negative predictor of outcome and length of hospital stay for elective surgical patients (1,2), 
and it is associated with increased mortality among those in intensive care (3). In the 
immediate phase after surgery insulin resistance is of peripheral origin, and as skeletal muscle 
accounts for ~80% of insulin stimulated glucose disposal it is considered the main site of 
impaired insulin response. While different means to improve insulin sensitivity and maintain 
glycemic control are generally recommended as part of elective surgery (4,5), tight glycemic 
control with insulin infusion reduces mortality for intensive care surgical patients (3).   
The incretin hormone glucagon like peptide-1 (GLP-1) is released postprandially from 
the small intestine and augments glucose-dependent release of insulin from pancreatic -cells 
during hyperglycemia, inhibits glucagon release and stimulates -cell proliferation (6). 
Incretin based therapies are now widely used in treatment of chronic insulin resistance and are 
increasingly being acknowledged to exhibit extra-pancreatic properties. GLP-1 has been 
shown to directly suppress hepatic endogenous glucose release (EGR) (7,8) and to improve 
insulin mediated glucose uptake in peripheral tissues (9 12). The latter is suggested to result 
from a direct effect of GLP-1 on myocytes by increasing glycogen synthesis through 
activation of intracellular insulin signalling (13 15), although such direct effects remain 
controversial (16 21). 
Thus, as GLP-1 may improve both insulin sensitivity and glycemic control (22) with 
practically no risk of hypoglycemia, it is a potential in-hospital therapeutic agent for acute 
conditions with reduced insulin sensitivity. The use of GLP-1 in surgical and ICU patients has 
not been put into clinical practise, although small scale clinical studies show promising results 
for improving glycemic control (23 28). No study has examined if GLP-1 also can diminish 
peripheral trauma-induced insulin resistance. The gold standard for measuring insulin 
sensitivity is the hyperinsulinemic euglycemic clamp (HEC) (29) and when combined with a 
glucose tracer, it can estimate both basal and insulin-stimulated hepatic and peripheral insulin 
sensitivity (30,31). 
Here, we utilized the euglycemic clamp technique to investigate if a perioperative 
infusion of GLP-1 could improve peripheral and hepatic insulin sensitivity after surgical 
trauma, with whole body glucose disposal (WGD) during HEC, as the primary 
outcome. Secondly, we evaluated intraoperative glycemic control, alterations in hormone 
release, glycogen content, intracellular insulin signalling and pancreatic -cell insulin 
secretion capacity after GLP-1 infusion to investigate the nature of such an effect. 
MATERIALS AND METHODS 
Animals, anesthesia and instrumentation. The protocols were approved by the 
committee of the Norwegian Experimental Animal Board and all experiments were conducted 
in compliance with the institutional animal care guidelines and the National Institute of 
Guide for the Care and Use of Laboratory Animals [Dept of Health and 
Human Services Publication no. (NIH) 85-23, revised 1985]. Female Yorkshire/Landrace 
hybrid pigs weighing ~29 kg were acclimatized at the animal research facilities for one week 
on a standardized diet and ad libitum access to water, but they were fasted 12 hours before the 
experiments. Experiments were commenced at 7 a.m. During all experiments, animals were 
sedated before orotracheal intubation and commencement of gas anaesthesia with isoflurane 
mixed with nitrous oxide/oxygen (40/60 %) together with infusions of fentanyl and 
midazolam (0.02 and 0.3 mg/kg/hr, respectively), as earlier described (31). An infusion of 
0.9% sodium chloride (Braun) at an initial load of 30 mL/kg/hr for the first 30 min was 
administered and continued at 10 mL/kg/hr throughout the experiment. Respiration was 
monitored through a Capnomac instrument (Datex, Tewksbury, MA, USA) and anaesthesia 
was adjusted according to blood gas analysis (ABL 800 FLEX; Radiometer, Copenhagen, 
Denmark) and snout reflex tests. Invasive arterial pressure and heart rate was monitored 
together with body temperature for surveillance. Normal porcine body core temperature at 
38.5 C° was maintained with heating blankets. At the end of the experiment on day two, the 
animals were euthanized with an infusion of pentobarbital (20 mg/kg).  
Study design and surgical intervention. Group sizes were estimated with power 
analysis on glucose clamp data from pilot experiments with GLP-1, as well as considering 
required group sizes in earlier clamp protocols (32). The pigs were examined in two 
consecutive experiments on separate experimental days (see figure 1). On experimental day 
one, animals were anesthetized, and preoperative basal glucose turnover and peripheral and 
hepatic insulin sensitivity were assessed by tracer infusion followed by two-step 
hyperinsulinemic-euglycemic clamping (HEC). Pancreatic insulin secretion capacity was 
assessed by a hyperglycemic clamp. Thereafter, the pigs were allowed 5 days for recovery 
and metabolic normalization. On experimental day two, animals were blindly randomized to 
receive surgery/control (n=7), surgery/GLP-1 (n=7) or a non-surgical sham/GLP-1 (n=5) 
intervention. Preoperative biopsies were then harvested immediately after onset of 
anaesthesia. GLP-1 infusion was commenced 15 min before onset of surgery at a rate of 10 
pmol/min/kg, shown to be safe and appropriate for porcine metabolism in pilot experiments 
and earlier studies (33,34). The infusion was discontinued after 145 min at the end of surgery. 
The two surgery groups were subjected to a midline laparotomy with resection of 1.5 m small 
bowel with primary anastomosis 1.5 m proximal to the ileocecal junction (duration ~2 hours) 
to avoid affecting the GLP-1 producing L-cells in the terminal ileum of the pig (35). Incisions 
were closed and postoperative basal glucose turnover, insulin sensitivity (HEC) and insulin 
secretion capacity (hyperglycemic clamp) were measured in the immediate postoperative 
phase. The sham/GLP-1 group received the same anaesthetic regimen, infusions and 
instrumentation within the same timeframe, but did not undergo surgery. Pre-, intra- and 
postoperative arterial blood samples (serum and plasma) and tissue biopsies from skeletal 
muscle and liver where collected serially throughout the experiments (figure 1).
Tracer infusion and hyperinsulinemic-euglycemic step clamp (HEC). Basal glucose 
turnover was assessed during the last 30 min of a 90 min primed (6 mg/kg), continuous (0.12 
mg/kg/min) infusion of D-[6,6-2H2]-glucose (basal period) (32). Thereafter, two consecutive 
120 min hyperinsulinemic euglycemic (~4.5 mmol/L) clamps with labelled glucose infusate 
(2.1 % atom percent enrichment, APE%) were performed. Insulin was infused at rates of 0.4 
mU/kg/min (low insulin clamp, HEC 1) and 1.2 mU/kg/min (high insulin clamp, HEC 2) to 
differentiate between hepatic and peripheral insulin sensitivity as previously described (31). 
Glucose infusion rates (GIR) of the labelled infusate were calculated as an average of the last 
40 min of each clamp. Tracer enrichment in arterial blood was measured by liquid 
chromatography with tandem mass spectrometry (LC-MS/MS) (31). Calculations of whole-
body glucose disposal (WGD) and endogenous glucose release (EGR) were performed based 
on modified vers (30). After estimation of basal glucose turnover 
rates, the increase in WGD (peripheral insulin sensitivity) and reduction in EGR (hepatic 
insulin sensitivity) during HEC were calculated, both pre- and postoperatively (31).  
 Hyperglycemic clamp. A glucose bolus (300 mg/kg) was administered over 45 seconds 
and glucose was clamped for 120 min at ~15 mmol/L as described with modifications (29). 
Insulin was measured every 2 min for the first 10 min, and thereafter every 10 min. 1st and 
2nd phase insulin secretion were calculated as area under the curve (AUC) for the first 10 min 
(AUC0-10) and for the remaining of the clamp (AUC10-120), respectively.
Hormones, free fatty acids and tissue glycogen. Serum insulin and plasma glucagon 
during clamps by RIA methods (Linco research, Inc., St. Charles, MO, USA). C-peptide was 
measured with a porcine ELISA kit (Mercodia, Uppsala, Sweden)(36). Serum cortisol was 
determined by electrochemiluminescence immunoassay (Roche Diagnostics, Basel, 
Switzerland)(37). Plasma FFA was measured using a colorometric assay kit (Wako 
Diagnostics, Richmond, VA, USA). Glycogen content in muscle and liver biopsies was 
determined as glucose units after hydrolysing macroglycogen and acid-insoluble proglycogen, 
using a hexokinase reagent kit (Horiba ABX, Montpellier, France).
 Western Blots. Skeletal muscle tissue ( 30 mg) was grinded and diluted in RIPA 
buffer, containing phosphatase and protease inhibitors (Roche, Basel, Switzerland). The 
protein concentrations were measured using a DC protein assay (Bio-rad, Hercules, CA, 
USA) with antibodies (Cell Signaling, Beverly, MA, USA) against total AKT(38), p-AKT 
(Ser473)(39), PI3K p85(40) and the secondary antibody anti-rabbit(41) anti-Actin (42) Sigma, 
Saint Louis, MO, USA) was used as loading control. Captured protein image was quantified 
using Image Studio (LI-COR, Lincoln Neb, USA) and expressed as fold-change from 
preoperative values.
Inflammation.  Pre- and postoperative plasma cytokines were analysed using a 
multiplex cytokine assay (Bio-Rad Laboratories Inc., Hercules, CA, USA) analysing TNF , 
IL-4, IL-6, IL-8, IL-10, IL1 , IFN  and IFN  on a Multiplex Analyser (Bio-Rad Laboratories) 
according to manufactures instructions. Porcine high sensitivity C-reactive protein (hs-CRP) 
with an ELISA kit (MyBioSource, San Diego, CA, USA)(43) according to manufactures 
instructions. 
Statistics. All values are displayed as mean ± SEM. Pre- to postoperative changes 
within the same group were -test. Relative changes from 
preoperative values (% or fold change) were calculated, and one-way ANOVA was used to 
detect differences between the groups with -hoc test. For comparison of 
repeated measures of hormones and glucose intraoperatively and for FFA profiles, two-way 
repeated measures ANOVA multiple comparisons was applied with post-hoc test. 
Differences were considered significant at P < 0.05.  
RESULTS
Hemodynamic measurements and monitoring. Pre- vs. intra- vs. postoperative 
hemodynamic measurements were stable and not different between groups including average 
heart rate (surgery/control; 95±5 vs. 112±5 vs. 96±6; surgery/GLP-1; 96±2 vs. 114±4 vs. 
115±5; sham/GLP-1 95±4 vs. 109±5 vs. 102±7 beats/min) and mean arterial pressure 
(surgery/control; 73±5 vs. 67±2 vs. 69±4;  surgery/GLP-1; 77±4 vs. 71±3 vs. 71±3; 
sham/GLP-1 73±4 vs. 71±2 vs. 71±2 mmHg). There were no further changes in 
hemodynamics during the glucose clamps (data not shown). Respiratory pre-, intra- and 
postoperative pCO2 values were stable and unchanged in and between groups (ranging from 
4.9-5.0 kPa), and as expected slightly increased during the clamps with no difference between 
groups (ranging from 5.9-6.0 kPa).  
Basal glucose turnover and glucose kinetics during two-step euglycemic clamping 
(HEC). Pre- and postoperative values for EGR and WGD during the basal period are 
displayed in table 1. No differences in basal EGR and WGD were found within or between 
the groups. Values for EGR and WGD during HEC are displayed in table 2 and the insulin-
mediated response is shown in figure 2.  In the surgery/control group, there was a reduction in 
both GIR (33%, P < 0.01) and insulin stimulated WGD (44%, P < 0.01) during HEC 2 
showing peripheral insulin resistance, while there was near normalization of total and 
peripheral insulin sensitivity in the surgery/GLP-1 group. GIR and WGD remained 
unchanged in the sham/GLP-1 group. During HEC 1 (low insulin), insulin stimulated 
suppression of EGR was unchanged from preoperative values in the surgery/control group, 
but significantly more suppressed in surgery/GLP-1 (40%, P < 0.05), and even more 
profoundly in sham/GLP-1 (104%, P < 0.05). During HEC 2 (high insulin), EGR was still 
more suppressed in surgery/GLP-1 (31%, P < 0.05), while no difference in EGR suppression 
was observed in the sham/GLP-1 group. Comparing group differences in total and peripheral 
insulin sensitivity, GIR and WGD in surgery/control were significantly more reduced than the 
two GLP-1 groups (P < 0.05, figure 3). 
Insulin, glucose and counter-regulatory hormones. Intraoperative levels of glucose, 
insulin, cortisol and glucagon are shown in figure 4. Glucose increased ~20% in 
surgery/control but was kept stable at baseline levels and was significantly lower in the GLP-
1 receiving groups (P < 0.05). In surgery/control, insulin remained unchanged, but there was a 
significant elevation of insulin levels in surgery/GLP-1 (P < 0.05). No group difference in 
sham/GLP-1 was found, but insulin increased within the group from 30-60 min after start of 
GLP-1 infusion (P < 0.05). Cortisol was unaffected by GLP-1, though the surgery groups had 
higher cortisol levels than sham/GLP-1 (P < 0.05). Intraoperative glucagon levels were 
unchanged in all groups. Pre- and postoperative levels of insulin, glucose and glucagon during 
the basal period are displayed in table 1. Despite increased intraoperative levels of circulating 
insulin during GLP-1 infusion, levels were equal in the postoperative phase within and 
between the groups. A postoperative increase in glucagon levels was seen in surgery/control 
(3.3-fold, P < 0.05), but was not evident in the GLP-1 groups. Insulin and counter-regulatory 
hormones were equal during HEC, confirming stable clamping conditions. 
Free fatty acids. Arterial plasma free fatty acid (FFA) concentrations were unchanged 
from preoperative levels and remained within the same range in all three groups during the 
postoperative basal period (surgery/control 228±54 vs. 285±51; surgery/GLP-1 252±42 vs. 
295±41; sham/GLP-1 176±16 vs. 178±39 µmol/L), and were equally suppressed during HEC 
1 (surgery/control 94±24; surgery/GLP-1 85±26; sham/GLP-1 114±30 µmol/L) and HEC 2 
(surgery/control 49±45; surgery/GLP-1 48±23; sham/GLP-1 23±10 µmol/L). 
Tissue glycogen content. Tissue glycogen levels are shown in table 3. As expected, 
surgical trauma led to a depletion of hepatic glycogen (82% reduction in both surgery groups, 
P < 0.05), but GLP-1 did not affect glycogen levels. Hepatic glycogen was slightly increased 
during HEC in the surgery/control group (26 %, P < 0.05) with a similar trend in the 
surgery/GLP-1 group (P < 0.14). Muscle glycogen content did not change in response to 
surgery nor GLP-1 in any of the groups. 
Insulin signalling proteins. Phosphorylated Akt (p-Akt) and PI3K p85 protein 
expression are shown in figure 5. As expected, Akt phosphorylation was elevated in response 
to insulin infusion during the clamp. GLP-1 had no effect on Akt phosphorylation. GLP-1 did 
not affect PI3K p85 expression in surgery/control or surgery/GLP-1, but significantly 
increased insulin stimulated PI3K-p85 in the sham/GLP-1 group (P < 0.05) with a similar 
trend in non-insulin stimulated expression (P=0.06).   
Hyperglycemic clamp. There was no difference in 1st phase insulin secretion from pre- 
to postoperative clamps in neither surgery/control (172±52 vs. 129±12 µU*min/mL), 
surgery/GLP-1 (232±56 vs. 197±43 µU*min/mL) or sham/GLP-1 (156±25 vs. 126±47 
µU*min/mL), nor were there any difference between the groups. 2nd phase insulin secretion 
was also unaffected by GLP-1, but higher circulating concentrations of insulin were seen after 
surgery (surgery/control 2563±667 vs. 3906±687 µU*min/mL, P < 0.05; surgery/GLP-1, 
2993±440 vs. 5892±1392 µU*min/mL, P < 0.05), but not in the sham/GLP-1 group 
(3706±544 vs 3241±666 µU*min/mL), most likely caused by the previously described 
reduction in insulin clearance in the immediate phase after surgery in pigs (31). 
Inflammatory biomarkers. IFN  was significantly reduced compared to preoperative 
measurements in the surgery/GLP-1 group (1.74±0.87 vs. 0.64±0.36 pg/mL, P < 0.05), but 
remained unchanged in the surgery/control (0.97±0.55 vs. 0.98±0.78 pg/mL) and sham/GLP-1 
group (0.47±0.20 vs. 0.43±0.24 pg/mL). A postoperative increase in IL-6 was only detectable 
in half of the pigs undergoing surgery and no differences were detected between the groups. 
There was no difference in IL-12 concentrations within or between the groups. TNF , IL-10, 
IL-4, IL1  and IFN  was below detection limits in all groups. There were no differences from 
pre- to postoperative levels in hs-CRP within or between groups (surgery/control; 12.07±2.50 
vs. 11.84±2.53 surgery/GLP-1; 12.89±2.44 vs. 13.33±3.14 sham/GLP-1 15.28±3.10 vs. 
14.94±2.54 mg/L).  
DISCUSSION
In the present study, we show that infusion of GLP-1 during major abdominal surgery 
prevents development of peripheral insulin resistance and increases hepatic insulin sensitivity 
in the immediate postoperative phase. 
Incretin-based therapies improve glycemic control in ICU patients (23,24,26), but have 
also been shown to be beneficial for elective surgical patients with preoperative metabolic risk 
factors (27) or for those undergoing major surgical procedures with high risk of 
hyperglycemia (25,28). Further, postoperative insulin resistance is associated with adverse 
postoperative outcome (44,45) while good intraoperative glycemic control improves insulin 
sensitivity after surgery (5). A crucial point during glucose regulation in acute insulin 
resistance is avoidance of hypoglycemia which augments morbidity and mortality (46). Thus, 
GLP-1, at least in theory, represents a safer approach to achieve glycemic control during and 
after surgery which can ease, decrease or even eliminate the use insulin infusions, reduce 
complications and contribute to improved postoperative outcome.  
Previous studies have suggested that GLP-1 may increase peripheral glucose uptake in 
healthy subjects through insulin-independent mechanisms (47,48), and studies in 
depancreatized dogs have shown that GLP-1 potentiates insulin-stimulated glucose utilization 
(49). However, several clamp studies on healthy human subjects shown conflicting results 
with no change in glucose uptake during superimposed GLP-1 infusion (8,17,19 21). A more 
recent study confirmed this finding during euglycemia, but showed that GLP-1 increases 
glucose uptake during hyperglycemia (50). Moreover, in most clamp studies on subjects with 
compromised insulin sensitivity (due to diabetes mellitus or high-fat feeding), GLP-1 
improved oxidative glucose disposal (9-12), although some studies does argue against this 
(51,52). During experimentally induced acute insulin resistance, GLP-1 restored the 
associated reduced glucose disposal (12). Hence, the present results support the notion that 
GLP-1 has a positive effect on WGD, but that this effect is limited to subjects were insulin 
sensitivity is already compromised, as after surgical trauma.  
GLP-1 infusion has been observed to reduce hepatic EGR, a finding which was 
previously attributed entirely to the regulation of pancreatic hormone release (16,18,52,53). 
However, more recent investigations show that even short-time treatment with GLP-1 
augments the suppressive effect of insulin on EGR (7), as supported by our findings. Other 
clamp-studies have failed to demonstrate a similar effect on EGR (52,54). However, this 
might  have been due to infusion of too high insulin doses during HEC with near complete 
suppression of EGR, potentially masking an effect of GLP-1 on hepatic insulin sensitivity (8). 
Our results support this view, as the difference in EGR in the sham/GLP-1 group was evident 
only during low insulin infusion, while higher insulin concentrations led to near total and 
equal suppression of EGR after GLP-1 infusion. 
The mechanisms underlying the effects of GLP-1 on peripheral insulin sensitivity have 
rarely been addressed in in vivo studies. Results from in vitro studies indicate that direct 
stimulation of the GLP-1 receptor (GLP-1R) which is expressed in several tissues, including 
myocytes may play a role (55). The prevailing view suggests a direct effect through regulating 
the PI3K-Akt pathway, leading to increased glucose uptake and tissue glycogen content, as 
shown in cell studies and in a clamp study on GLP1-R knockout mice (14,15,56). However, 
other in vivo studies have failed to demonstrate any effect of GLP-1 on glycogen storage in 
peripheral tissues (57,58). Trauma does lead to depletion of hepatic glycogen (59), as it did in 
both surgery groups in our study. Thus, our results did not demonstrate any effect of GLP-1 
on glycogen storage, and as no effect of GLP-1 was seen on Akt activation, this questions a 
direct effect on myocytes in the present study. A slight increase in PI3K expression was 
evident in the sham/GLP-1 group as earlier reported (56), but not in the surgery/GLP-1 group. 
Hence, GLP-1 could  have an effect on PI3K regulation as has been demonstrated in in vitro 
studies, but  this effect does not seem to be involved in increasing WGD after surgery in our 
study. Taken together, our data indicate that GLP-1 exerts its effects on muscle glucose 
uptake and oxidative disposal through other mechanisms than through the previously 
suggested direct myocyte regulation.  
Improved intraoperative glycemic control should be ascribed mainly to the increased 
intraoperative insulin levels induced by GLP-1, possibly aided by increased microcirculatory 
perfusion (12). Dysregulated glucose homeostasis increases inflammation, while 
hyperglycemic metabolic stress would lead to increased levels of reactive oxygen species, 
both known to induce insulin resistance and both shown to be counteracted by GLP-1 (60,61). 
Thus, improved intraoperative glycemic control itself could indirectly improve postoperative 
insulin sensitivity, as demonstrated by Blixt et al. (5). As a direct effect does not appear to 
explain the improved insulin sensitivity, improved glycemic control seems to be the main 
factor contributing to improved insulin sensitivity in our study as well. Although there were 
no major changes in plasma cytokines in the present study, the reduced IFN  levels in the 
GLP-1/surgery group indicate an immunomodulatory mechanism. Finally, it has also been 
suggested that GLP-1 can modulate the release of FFA, which indirectly could induce insulin 
resistance in skeletal muscle. Results from human studies did not find GLP-1 to exert these 
properties (62)  which is in concert with our findings. 
In the postoperative phase, endogenous insulin remained at preoperative levels in all 
groups, and as levels of insulin during clamping were equal and our HEC method suppresses 
pancreatic function to near completeness (31), the clamp results were not affected by 
differences in endogenous insulin release. The moderate postoperative increase in glucagon 
levels was antagonized by GLP-1 treatment. This is in agreement with a clinical study on 
elective surgical patients with diabetes (28), and could partly explain the positive effect on 
postoperative EGR. However, as the EGR was in fact more supressed after GLP-1 infusion 
compared to values before the intervention in the normal sensitive GLP-1/sham group, this 
indicates, at least in part, a direct effect of GLP-1 on the liver, as glucagon levels were 
unchanged in this group. As expected, GLP-1 did not affect postoperative pancreatic insulin 
secretion capacity, an effect more likely to occur after long-lasting GLP-1 therapy (6).  
 This study has limitations. Paired experiments were performed to minimize metabolic 
variance and while the effects on insulin sensitivity were quite clear, it is difficult to eliminate 
that any other differences have been overlooked with limited group sizes. The anaesthesia 
protocol was designed to minimize any metabolic effect, but it should be noted that isoflurane 
is known to affect glucose metabolism to a certain degree. The increase in glucose disposal 
without any effect on tissue glycogen content indicates that glucose oxidation was increased 
by GLP-1. However, glucose oxidation rates were not directly measured and an increase in 
alternative non-oxidative glucose disposal cannot be excluded. Specific studies on GLP-1 
with e.g. indirect calorimetry combined with HEC and extended insulin signalling pathway 
measurements are needed to further determine the fate of the disposed glucose. Finally, we 
did not observe any clear effect on all inflammatory biomarkers. As earlier acknowledged in 
anesthetized pigs (63), basal cytokine levels are suppressed and low, hence studies with 
longer observational time and tissue specific analyses are necessary to determine any certain 
anti-inflammatory effect of GLP-1. 
 In conclusion, we show that GLP-1 along with improving glycemic control almost 
completely abolishes postoperative peripheral insulin resistance, probably due to maintained 
oxidative glucose disposal, but not through a direct effect on the Akt-PI3K pathway or 
glycogen content in skeletal muscle. A favourable antagonistic effect on glucagon release and 
an increase in hepatic insulin sensitivity from preoperative levels was also seen after surgery. 
This study suggests that use of GLP-1 for prevention and treatment of trauma-induced insulin 
resistance could provide beneficial metabolic effects for surgical patients.  
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Figure 1. Study design. 
Time course of the two experimental days for instrumentation (instr.), pre- and postoperative 
metabolic basal metabolism, hyperinsulinemic euglycemic clamps (HEC) and hyperglycemic 
clamp (HC). Time points of essential pre-, intra- and post-operative blood sampling ( ) and 
biopsy harvesting (o) are shown. During basal period, HEC and HC, plasma glucose was 
measured continuously, and blood samples for hormones and FFA was collected serially 
(every 30 min) indicated by grey arrow. 
Figure 2. Insulin-mediated response during hyperinsulinemic euglycemic clamping. 
Changes from basal glucose turnover in pre- (white bars) and postoperative (black bars) 
endogenous glucose release (EGR) and whole body glucose disposal (WGD) in response to 
insulin, as determined by two-step hyperinsulinemic (0.4 and 1.2 mg insulin/kg/min) 
euglycemic clamping. Values are mean ± SEM. *, P < 0.05; **, P < 0.01 vs. preoperative 
-test). 
 
Figure 3. Pre- to post-operative changes in total and peripheral insulin sensitivity. 
Percent changes (from pre- to postoperative measurements) within each group for steady state 
glucose infusion rate (SS GIR) and whole body glucose disposal (WGD), as measured during 
high insulin clamp. Values are mean ± SEM. *, P < 0.05; **, P < 0.01 vs. preoperative (one-
way ANOVA).  
 
 
Figure 4. Intraoperative glucose and hormone levels.
Intraoperative changes from preoperative levels in (a) serum glucose (%) change, (b) serum 
levels of insulin and (c) cortisol and (d) plasma glucagon. Values are mean ± SEM. Repeated 
measures two- , P < 0.01 vs. preoperative levels 
within the group and *P < 0.05 in difference by group (and time).
Figure 5. Pre- to post-operative changes in insulin signalling proteins.
Postoperative protein expression of (a) p/t-Akt and (b) PI3K p85 in snap-frozen biopsies from 
skeletal muscle harvested during the non-insulin stimulated (non-ins) basal period and during 
insulin-stimulated (ins-stim) clamp, expressed as fold-change from preoperative 
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